9 completed. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 3 | 1 | Completed 1 |
Follow Germ Cell Tumor: new trials by email Literature Review of Germ Cell Tumor trials Research Report on Germ Cell Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD30 CAR for CD30+ NSGCT ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 2 | 2022-12-09 | 2026-07-07 |
| Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin) - Germ Cell Tumor, Yolk Sac Tumor | Phase 2 | Completed | Shandong First Medical University | 20 | 2021-11-11 | 2025-09-18 |
| A Phase II Trial of Cabozantinib With Patients With Refractory GCTs Cabozantinib - Germ Cell Tumor, Seminoma | Phase 2 | Completed | Jennifer King | 50 | 2021-06-10 | 2026-10-16 |
| Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children - Germ Cell Tumor, Yolk Sac Tumor | Phase 2 / Phase 3 | Completed | Shandong First Medical University | 32 | 2020-06-01 | 2025-09-19 |
| Disulfiram and Cisplatin in Refractory TGCTs. Disulfiram - Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute, Slovakia | 12 | 2019-05-14 | 2023-10-04 |
| Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Memantine, Placebo, Cognitive Assessment - Glioma of Brain, Craniopharyngioma | Phase 2 | Completed | St. Jude Children's Research Hospital | 41 | 2017-11-07 | 2026-06-23 |
| First Line TIP in Poor Prognosis TGCTs. Paclitaxel, Ifosfamide, Cisplatin - Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute, Slovakia | 19 | 2015-04-01 | 2020-08-07 |
| A Pilot RCT of the PRISM Intervention for AYAs With Cancer Promoting Resilience In Stress Management (PRISM) - Cancer, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Seattle Children's Hospital | 92 | 2015-01-30 | 2024-04-09 |
| Everolimus in Refractory Testicular Germ Cell Cancer Everolimus - Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute, Slovakia | 15 | 2011-11-01 | 2016-01-12 |
Neoplasms, Germ Cell and Embryonal (9) · Brain Neoplasms (2) · Endodermal Sinus Tumor (2) · Nonseminomatous germ cell tumor (2) · Craniopharyngioma (1) · Ependymoma (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Sarcoma (1) · Seminoma (1)
Neoplasms by Histologic Type (9) · Neoplasms (8) · Brain Diseases (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Mesonephroma (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Disease Attributes (1) · Germinoma (1) · Glioma (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1)
130-nm albumin-bound paclitaxel (1) · Cisplatin (1) · Cyclophosphamide (1) · Disulfiram (1) · Drug Therapy (1) · Everolimus (1) · Ifosfamide (1) · Medication Errors (1) · Memantine (1) · Mental Status and Dementia Tests (1) · Paclitaxel (1) · cabozantinib (1) · fludarabine (1) · fludarabine phosphate (1)
National Cancer Institute, Slovakia (3) · Shandong First Medical University (2) · Jennifer King (1) · Seattle Children's Hospital (1) · St. Jude Children's Research Hospital (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (4) · Slovakia (3) · China (2)
Jingfu Wang, MD (2) · Abby R Rosenberg, MD, MS (1) · Heather M. Conklin, PhD (1) · Jennifer King, MD (1) · Jozef Mardiak, Prof (1) · Matthew I Milowsky (1) · Michal Mego, Ass.prof (1) · Michal Mego, Ass.prof. (1) · Michal Mego, Prof (1)
PMID 31037789, PMID 31680625, PMID 33960833, PMID 34817581
R21CA218625 (1)